Higher risk of VTE in CKD surgical patients on enoxaparin

Higher risk of VTE in CKD surgical patients on enoxaparin
For patients with chronic kidney disease who undergo total hip replacement, the rate of major venous thromboembolism is significantly higher in those treated with enoxaparin compared to those treated with desirudin, according to a study published online June 4 in the Journal of Thrombosis and Haemostasis.

(HealthDay) -- For patients with chronic kidney disease (CKD) who undergo total hip replacement (THR), the rate of major venous thromboembolism (VTE) is significantly higher in those treated with enoxaparin compared to those treated with desirudin, according to a study published online June 4 in the Journal of Thrombosis and Haemostasis.

Andrew F. Shorr, M.D., M.P.H., of the Washington Hospital Center in the District of Columbia, and colleagues conducted a post-hoc subgroup analysis of a multicenter, randomized, double-blind study of 577 patients with stage 3B or worse CKD who were treated with desirudin or after elective THR. Thrombosis and bleeding outcomes were assessed for participants who received desirudin, 15 mg twice daily, or enoxaparin, 40 mg/day, administered subcutaneously.

The researchers found that the proportion of patients who experienced a major VTE was significantly higher in the enoxaparin group versus the desirudin group (11.1 versus 3.4 percent; model-adjusted odds ratio, 3.52). The rate of major bleeding did not differ significantly between groups, regardless of patient renal function.

"CKD has been reported previously to increase the risk of bleeding with anticoagulants and these findings suggest that CKD may also increase risk of major VTE for patients treated with enoxaparin, but not for patients treated with desirudin," the authors write. "Clinicians should consider the impact of CKD on risk of VTE when choosing a prophylaxis agent."

Several authors disclosed to Canyon Pharmaceuticals Inc., which funded the study and manufactures desirudin.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Prophylaxis with apixaban feasible for cancer patients

date Mar 29, 2012

(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic ...

Recommended for you

WHO shake-up approved after Ebola debacle

date 15 hours ago

The World Health Organization got the go-ahead Tuesday for a sweeping shake-up, including a $100-million war chest to battle future emergencies following the Ebola fiasco.

Soy supplements don't improve asthma

date 16 hours ago

Despite previous findings suggesting a link between soy intake and decreased asthma severity, a new study from Northwestern Medicine and the American Lung Association Asthma Clinical Research Network shows ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.